Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission
Standard
Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. / Mischnik, Alexander; Baumert, Philipp; Hamprecht, Axel; Rohde, Anna; Peter, Silke; Feihl, Susanne; Knobloch, Johannes K.-M.; Gölz, Hanna; Kola, Axel; Obermann, Birgit; Querbach, Christiane; Willmann, Matthias; Gebhardt, Friedemann; Tacconelli, Evelina; Gastmeier, Petra; Seifert, Harald; Kern, Winfried V; DZIF-ATHOS Study Group .
In: INT J ANTIMICROB AG, Vol. 49, No. 2, 02.2017, p. 239-242.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission
AU - Mischnik, Alexander
AU - Baumert, Philipp
AU - Hamprecht, Axel
AU - Rohde, Anna
AU - Peter, Silke
AU - Feihl, Susanne
AU - Knobloch, Johannes K.-M.
AU - Gölz, Hanna
AU - Kola, Axel
AU - Obermann, Birgit
AU - Querbach, Christiane
AU - Willmann, Matthias
AU - Gebhardt, Friedemann
AU - Tacconelli, Evelina
AU - Gastmeier, Petra
AU - Seifert, Harald
AU - Kern, Winfried V
AU - DZIF-ATHOS Study Group
N1 - Copyright © 2016. Published by Elsevier B.V.
PY - 2017/2
Y1 - 2017/2
N2 - As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25-4 mg/L for cefepime/tazobactam, 0.25-2 mg/L for ceftazidime/avibactam, 0.125-0.5 mg/L for ceftaroline/avibactam, 0.5-4 mg/L for cefpodoxime/clavulanic acid and 0.25-1 mg/L for aztreonam/avibactam, depending on the underlying resistance mechanism and organism. Based on in vitro testing, β-lactam antibiotics play an important role in the treatment of infections due to β-lactamase-producing organisms.
AB - As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25-4 mg/L for cefepime/tazobactam, 0.25-2 mg/L for ceftazidime/avibactam, 0.125-0.5 mg/L for ceftaroline/avibactam, 0.5-4 mg/L for cefpodoxime/clavulanic acid and 0.25-1 mg/L for aztreonam/avibactam, depending on the underlying resistance mechanism and organism. Based on in vitro testing, β-lactam antibiotics play an important role in the treatment of infections due to β-lactamase-producing organisms.
U2 - 10.1016/j.ijantimicag.2016.10.013
DO - 10.1016/j.ijantimicag.2016.10.013
M3 - SCORING: Journal article
C2 - 27939093
VL - 49
SP - 239
EP - 242
JO - INT J ANTIMICROB AG
JF - INT J ANTIMICROB AG
SN - 0924-8579
IS - 2
ER -